Detecting Rare T-Cell Responses at Scale with ELISpot and FluoroSpot
WEBINAR
Discover sensitive, robust cell-based immunoassays, ELISpot and FluoroSpot, for detecting rare antigen-specific T-cell responses at the single-cell level. See how you can multiplex cytokine detection with FluoroSpot to achieve high throughput, save on precious sample, and get more data from a single well compared to ELISpot.
In this webinar, you will learn:
- The key applications of ELISpot and FluoroSpot in measuring T-cell responses to vaccines, biotherapeutics, and cell and gene therapies.
- How to set up and execute these assays.
- How to multiplex cytokine detection using FluoroSpot.
- The qualification of these assays for use in preclinical and clinical trials.
Finding an assay method sensitive enough to detect rare T-cell responses while being efficient enough to process large sample sizes is challenging.
ELISpot and FluoroSpot are cell-based immunoassays for measuring cytokine and antibody secretion from activated immune cells at the single-cell level.
They are sensitive, robust, and easy to perform, making them ideal for detecting rare antigen-specific T-cell responses in basic research and across various stages of drug development, including clinical trials.
Due to their high sensitivity and ease of use, ELISpot and FluoroSpot are often preferred over flow cytometry, particularly when high-throughput screening is required.
Join us in this webinar and learn how ELISpot and FluoroSpot can help streamline your workflows in drug development and beyond!
Speakers

Renata Varnaite, PhD
Field Application Scientist, Mabtech
Renata Varnaite completed her PhD in Medical Science at Karolinska Institutet, Sweden in 2022. During her research studies, she utilized FluoroSpot assays to measure human T-cell and B-cell responses to infections and vaccines. Having joined Mabtech in 2023 she helps Mabtech’s customers to effectively apply ELISpot/FluoroSpot technology in different therapeutic areas, from infectious disease vaccines to cell and gene therapies.

Jun Park, PhD
Merck
R&D Manager
Jun Park, PhD, is the R&D manager at Merck. He studied Biomaterials and Immunology at the University of Toronto and did his postdoctoral work at Harvard Medical School investigating small molecule regulators of beta integrins. Since joining Merck in 2006, his primary works have focused on novel detection technologies and cell-based assays.

Bryan Simons, PhD
Manager - I&I Science Lead (US)
Bryan Simons completed his PhD in Toxicology at the University of Montana in 2015. In 2017, he joined the Labcorp – Madison Immunology & Immunotoxicology group as a subject matter expert in flow cytometry and cell-based assays. Since 2022, he has led a team of SMEs focused on developing and validating cell-based assays for investigating immunotoxicity and therapeutic potential of new drug products ranging from large molecules to cell and gene therapies.
Mammalian cell culture
- Primary cell culture
期间:1h
语言:English
场次 1:往期 May 21, 2025
如要继续阅读,请登录或创建帐户。
暂无帐户?